Financial News

Financial Report: Patheon

Revenues up 10% with continued growth across sterile and oral solid dose forms

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Patheon 4Q Revenues: $510 million (+10%) 4Q Earnings: $44.1 million (earnings were $147.4 million 4Q15) FY Revenues: $1.9 billion (+5%) FY Earnings: $31.7 million (earnings were $138.4 million FY15) Comments: Despite temporary closures at two sites, the DPS segment sales were $298 million with continued volume growth and demand across sterile and oral solid dose forms. PDS sales were $60 million, primarily driven by strong demand for sterile and low-solubility services. The Drug S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters